Contact
Anchoring retinal therapies
for lasting vision
Developing long-acting biologics designed to anchor within the vitreous and extend the time between treatments for retinal disease.
01
The Opportunity
Anti-VEGF therapy doesn't fail patients. The burden of treatment does.
Today’s anti-VEGF therapies can effectively control retinal disease, but require ongoing visits and injections that are difficult to sustain over time for patients, physicians and payers. The result can be undertreatment and preventable vision loss.¹
15–20
years
treatment horizon
40%
discontinue within
one year
45 M
patients worldwide
$20 B+
global opportunity,
lead indication
02
Optigo's Solution
A novel approach to
durable retinal therapy.
Optigo's Vitreous Anchor Platform pairs a proven therapeutic protein with a hyaluronan-binding anchor in a single molecule. Once injected, the anchor binds to hyaluronan in the vitreous, creating a reservoir designed to slow elimination. In preclinical models, this approach has extended ocular half-life and drug exposure.*
Want the data behind it?
Contact us
Target Profile
One molecule with two functions: vitreous anchoring + therapeutic activity
Uses eye's natural proteins to anchor and delay vitreous elimination
Delivered by standard intravitreal injection, with
no implant or device
The goal: Higher, more durable anti-VEGF concentrations with fewer injections and potentially no loading doses
Injections over 12 months
Illustrative
Month 0
Month 6
Month 12
Effective, but cleared over time
Conventional anti-VEGF molecules gradually clear from the eye, requiring repeat injections to maintain disease control.
One injection over 12 months
Illustrative
Month 0
Month 6
Month 12
Injected, anchored and released over time*
The hyaluronan-binding domain anchors the molecule within the vitreous, creating a reservoir designed to replenish the free, active fraction and extend ocular exposure.
*Preclinical: >10x extension of ocular PK in non-human primates; translational modeling supports a target of one injection every 9-12 months. A model-based target, not a demonstrated result.
2x
Eyecelerator™ People’s Choice
Award winner, 2025–2026
Eyecelerator™
People’s Choice
Award winner,
2025–2026
03
Platform & pipeline
The Vitreous Anchor Platform:
built for retinal biologics
Designed for compatibility with multiple protein-based modalities, including antibodies, antibody fragments and other therapeutic proteins. This approach could support longer-acting biologics across multiple retinal diseases.
Program
Discovery
Preclinical Development
Clinical Development
XPK-640
Lead nAMD Program
Bi-functional long-acting Aflibercept-based NBE for nAMD
Bifunctional fusion protein expressed
as a single polypeptide chain
Aflibercept
Therapeutic domain
Hyaluronan-binding domain
Vitreous anchor
Preclinical Evidence
>10x
extension of ocular PK in NHP
~36 days
ocular half-life in NHP
9-12 mo
target dosing interval, based on
translational modeling
NHP, non-human primate. The 9-12 month interval is a model-based target,
not a demonstrated result.
XPK-700
Geographic Atrophy
Bi-functional long-acting NBE for GA
XPK-800
Uveitic Macular Edema
Bi-functional long-acting NBE for UME
Platform
Partnering
Vitreous Anchor Platform with the potential to extend the durability of partner biologics
Discovery
Preclinical Development
Clinical Development
XPK-640
Lead nAMD Program
Bi-functional long-acting Aflibercept-based NBE for nAMD
Bifunctional fusion protein expressed as a single polypeptide chain
Aflibercept
Therapeutic domain
Hyaluronan-binding domain
Vitreous anchor
Preclinical Evidence
>10x
extension of ocular PK in NHP
~36 days
ocular half-life in NHP
9-12 mo
target dosing interval, based on translational modeling
NHP, non-human primate. The 9-12 month interval is a model-based target, not a demonstrated result.
XPK-700
Geographic Atrophy
Bi-functional long-acting NBE for GA
XPK-800
Uveitic Macular Edema
Bi-functional long-acting NBE for UME
Platform
Partnering
Vitreous Anchor Platform with the potential to extend the durability of partner biologics
Built by leaders in ophthalmic drug development.
Optigo brings together experience advancing ophthalmic therapies from discovery through development, supported by regulatory experts and leading retina specialists.
Arshad Khanani, MD, MA, FASR
Chair Scientific Advisory Board
- Premier clinical investigator specializing in novel gene therapies, advanced drug delivery systems, and biosimilars
- Leads 160+ scientific publications and serves as Director of Clinical Research at Sierra Eye Associates
- Global principal investigator for multiple breakthrough phase III trials transforming macular degeneration treatment
Robert Avery, MD
Clinical KOL
- 30+ years experience in ophthalmology, pioneered anti-VEGF therapy in retinal disease
- Leads over 30 active clinical trials via California Retina Research Foundation
- Internationally recognized leader in retinal innovation, drug delivery, and venture-backed ophthalmology startups
David Boyer, MD
Clinical KOL
- Senior clinical innovator and Senior Partner at Retina-Vitreous Associates Medical Group in Southern California
- Renowned investigator driving top-tier trials for geographic atrophy, dry AMD, & suprachoroidal gene delivery
- Influential academic voice serving as Adjunct Clinical Professor of Ophthalmology at the Keck School of Medicine of USC
Hemal Mehta, MD
Clinical KOL
- Cambridge MD and Moorfields-trained medical retina specialist and cataract surgeon
- Leads over 50 clinical trials as Co-director of Clinical Trials Research at Strathfield Retina Clinic, Australia
- Internationally recognized registry leader: Steering Committee member for Fight Retinal Blindness! project and Medical Retina Section Editor for Eye Journal
05
Latest news
Company progress and milestones.
Follow Optigo's latest development, data and company updates.
Let's talk about lasting vision.
Connect with the Optigo team to discuss investment, partnership opportunities or the science behind the platform.
How it works
